Elutia (ELUT) Net Income towards Common Stockholders (2019 - 2026)
Elutia recorded quarterly Net Income towards Common Stockholders of -$7.5 million in Q1 2026, down 113.02% quarter-over-quarter from $57.4 million in Q4 2025, and up 18.23% year-over-year from -$6.3 million in Q1 2025.
Elutia's Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$7.5 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 18.23% year-over-year to -$7.5 million; the TTM figure through Mar 2026 stood at $31.3 million (up 169.13% YoY), while the FY2025 annual figure was $40.0 million, up 174.06% from the prior year.
- Net Income towards Common Stockholders came in at -$7.5 million for Q1 2026 at Elutia, down from $57.4 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $57.4 million in Q4 2025 to a low of -$28.2 million in Q2 2024.
- A 5-year average of -$5.9 million and a median of -$9.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 733.12% in 2025 and fell as far as 940.3% in 2025.
- Elutia's Net Income towards Common Stockholders stood at -$2.7 million in 2022, then slumped by 372.78% to -$12.9 million in 2023, then gained by 29.8% to -$9.1 million in 2024, then jumped by 733.12% to $57.4 million in 2025, then plunged by 113.02% to -$7.5 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$7.5 million, $57.4 million, and -$9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 199.50 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Elutia | 45.79 Mn | 17.31 Mn | 1.80 Mn | -7.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.47 Mn |
| Dec 31, 2025 | 17.46 Mn |
| Sep 30, 2025 | -8.97 Mn |
| Jun 30, 2025 | -11.84 Mn |
| Mar 31, 2025 | -9.13 Mn |
| Dec 31, 2024 | -9.06 Mn |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | -28.18 Mn |
| Mar 31, 2024 | -17.99 Mn |
| Dec 31, 2023 | -9.31 Mn |
| Sep 30, 2023 | -9.75 Mn |
| Jun 30, 2023 | -7.73 Mn |
| Mar 31, 2023 | -9.78 Mn |
| Dec 31, 2022 | -8.73 Mn |
| Sep 30, 2022 | -9.91 Mn |
| Jun 30, 2022 | -9.40 Mn |
| Mar 31, 2022 | -8.15 Mn |
| Dec 31, 2021 | -9.06 Mn |
| Sep 30, 2021 | -8.32 Mn |
| Jun 30, 2021 | -2.39 Mn |
| Mar 31, 2021 | -5.07 Mn |
| Dec 31, 2020 | -5.36 Mn |
| Sep 30, 2020 | -10.24 Mn |
| Jun 30, 2020 | -5.18 Mn |
| Mar 31, 2020 | -4.56 Mn |
| Dec 31, 2019 | -2.78 Mn |
| Sep 30, 2019 | -3.10 Mn |